| scholarly article | Q13442814 |
| P2093 | author name string | N Takahashi | |
| T Ishikawa | |||
| H Tsumura | |||
| T Ishihara | |||
| N Kobayashi | |||
| M Goto | |||
| T Miura | |||
| S Sakuma | |||
| Y Miyao | |||
| K Maeta | |||
| K Okimura | |||
| A Ueno | |||
| N Kano | |||
| F Kinugasa | |||
| P2860 | cites work | CD40-CD40 ligand | Q28143324 |
| IgG receptor polymorphisms: risk factors for disease | Q33503157 | ||
| CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates | Q34433847 | ||
| Tolerance and near-tolerance strategies in monkeys and their application to human renal transplantation | Q34487760 | ||
| Production of human monoclonal and polyclonal antibodies in TransChromo animals | Q34634571 | ||
| What's in the pipeline? New immunosuppressive drugs in transplantation | Q35025829 | ||
| The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease | Q35197406 | ||
| Soluble CD40 ligand induces β 3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling | Q36350146 | ||
| A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression | Q36447586 | ||
| CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis | Q37696199 | ||
| Long-term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates | Q39640425 | ||
| Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. | Q40459668 | ||
| Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation | Q40578442 | ||
| CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. | Q40658295 | ||
| Anti-CD40 therapy extends renal allograft survival in rhesus macaques | Q44190483 | ||
| Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model. | Q44839204 | ||
| Absence of CD40 signaling is associated with an increase in intimal thickening after arterial injury | Q46113707 | ||
| IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates | Q46427141 | ||
| ASKP1240, a fully human anti-CD40 monoclonal antibody, prolongs pancreatic islet allograft survival in nonhuman primates | Q48032381 | ||
| Protection of marmoset monkeys against EAE by treatment with a murine antibody blocking CD40 (mu5D12). | Q48494762 | ||
| Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways | Q56908183 | ||
| Human platelet aggregation by murine monoclonal antiplatelet antibodies is subtype-dependent | Q58481523 | ||
| Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40 | Q62604578 | ||
| CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism | Q63354517 | ||
| Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies | Q69522036 | ||
| Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40 | Q72093299 | ||
| Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates | Q73134598 | ||
| Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand | Q73401367 | ||
| Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics | Q73627238 | ||
| CD154 (CD40 ligand)-deficient mice exhibit prolonged bleeding time and decreased shear-induced platelet aggregates | Q73690749 | ||
| Prevention of experimental colitis in SCID mice reconstituted with CD45RBhigh CD4+ T cells by blocking the CD40-CD154 interactions | Q73812280 | ||
| CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression | Q74310001 | ||
| The immunobiology of inductive anti-CD40L therapy in transplantation: allograft acceptance is not dependent upon the deletion of graft-reactive T cells | Q74464420 | ||
| Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates | Q77890140 | ||
| A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys | Q81567977 | ||
| The role of CD40 in CD40L- and antibody-mediated platelet activation | Q81873162 | ||
| A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy | Q84056960 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1290-1299 | |
| P577 | publication date | 2014-04-14 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects | |
| P478 | volume | 14 |
| Q92522477 | A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation |
| Q90154642 | CD11b is a novel alternate receptor for CD154 during alloimmunity |
| Q40256254 | CD40 Generation 2.5 Antisense Oligonucleotide Treatment Attenuates Doxorubicin-induced Nephropathy and Kidney Inflammation. |
| Q50614844 | Comparative Evaluation of αCD40 (2C10R4) and αCD154 (5C8H1 and IDEC-131) in a Nonhuman Primate Cardiac Allotransplant Model. |
| Q37375148 | Costimulation Blockade in Kidney Transplantation: An Update |
| Q36484383 | Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis |
| Q38786418 | Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation |
| Q90599620 | High Dimensional Renal Profiling: Towards a Better Understanding or Renal Transplant Immune Suppression |
| Q34484801 | Immunosuppressive Medications |
| Q53102364 | Mechanisms of Mixed Chimerism-Based Transplant Tolerance. |
| Q38445344 | Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance |
| Q37662989 | Old game, new players: Linking classical theories to new trends in transplant immunology |
| Q55552584 | Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis. |
| Q38728589 | Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation. |
Search more.